Sonnet Biotherapeutics Holdings, INC
Market Movers (8-K)
Hyperliquid Strategies Inc. (HSI) has completed its business combination with Sonnet BioTherapeutics Holdings, Inc., with HSI common stock set to trade on Nasdaq under 'PURR'.
Capital raise
Sonnet BioTherapeutics Holdings, Inc. announced its stockholders approved the proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC.
Sonnet BioTherapeutics Holdings, Inc. adjourned its special meeting of stockholders to December 2, 2025, seeking more votes for its proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC.
Delay expected
Worse than expected
Sonnet BioTherapeutics Holdings, Inc. stockholders approved all four proposals, including director elections and auditor ratification, at their Annual Meeting on September 26, 2025.
Sonnet BioTherapeutics Holdings, Inc. has entered into a formal employment agreement with interim Chief Executive Officer Raghu Rao, outlining his base salary, performance bonuses, and severance terms.
Sonnet BioTherapeutics Holdings, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a successful private placement and warrant exercises totaling approximately $16 million.
Capital raise
Better than expected
Quarterly Earnings (10-Q)
Sonnet BioTherapeutics reported increased net losses for the nine months ended June 30, 2025, while advancing its clinical pipeline and announcing a definitive merger agreement with Hyperliquid Strategies Inc.
Delay expected
Worse than expected
Capital raise
Sonnet BioTherapeutics reports its financial results for the quarter ended March 31, 2025, highlighting clinical trial advancements and pipeline development amid ongoing financial challenges.
Capital raise
Worse than expected
Sonnet BioTherapeutics reports its financial results for the quarter ended December 31, 2024, and provides an update on its clinical programs and recent developments.
Worse than expected
Delay expected
Capital raise
10-Q: Sonnet BioTherapeutics Reports Q3 2024 Results, Cites Ongoing Clinical Progress and Cost Management
Sonnet BioTherapeutics reported its Q3 2024 financial results, highlighting clinical trial advancements and ongoing cost-cutting measures.
Worse than expected
Delay expected
Capital raise
Sonnet BioTherapeutics reported its Q2 2024 financial results, highlighted by a net income of $365,425 and the establishment of a $25 million committed equity facility.
Better than expected
Delay expected
Capital raise
Sonnet BioTherapeutics reported a net loss of $1.2 million for the quarter ended December 31, 2023, while implementing cost-cutting measures and advancing clinical programs.
Worse than expected
Delay expected
Capital raise
Annual Reports (10-K)
Sonnet Biotherapeutics Holdings, Inc. files an amended annual report (10-K/A) for the fiscal year ended September 30, 2025, primarily to correct the auditor's report.
Capital raise
Sonnet BioTherapeutics reported a significant increase in net loss for fiscal year 2025, driven by higher R&D and administrative costs, while advancing its oncology pipeline and completing a business combination.
Worse than expected
Capital raise
Delay expected
Sonnet BioTherapeutics, a clinical-stage oncology company, reported significant progress in its clinical programs and strategic initiatives for fiscal year 2024, despite facing financial challenges.
Worse than expected
Delay expected
Capital raise
Insider Trading (Form 4)
Sonnet BioTherapeutics Chief Medical Officer Richard T. Kenney reported significant changes in his beneficial ownership following the company's merger with Hyperliquid Strategies Inc.
Sonnet BioTherapeutics' Chief Business Officer, Stephen J. McAndrew, reported the disposition of 6,446 common shares following the company's business combination with Hyperliquid Strategies Inc.
Sonnet BioTherapeutics CFO Donald J. Griffith reported the disposition of all 10,375 common shares following the company's merger into Hyperliquid Strategies Inc.
Sonnet BioTherapeutics Director Lori McNeill exchanged 4,394 common shares for Hyperliquid Strategies stock and CVRs following a business combination.
Sonnet BioTherapeutics Director Susan Dexter reported the disposition of 9,643 common shares, converting them into Hyperliquid Strategies Inc. stock and CVRs following a business combination.
Sonnet BioTherapeutics Holdings, Inc. CEO Raghu Rao reported the exchange of 22,356 vested restricted stock units for Hyperliquid Strategies Inc. common stock and CVRs following a business combination.
Proxy Statements (Def-14A)
Sonnet BioTherapeutics Holdings, Inc. has adjourned its special meeting of stockholders to allow more time for voting on a proposed business combination.
Worse than expected
Delay expected
Sonnet BioTherapeutics is set to merge with Hyperliquid Strategies Inc. (Pubco), transforming into a digital asset treasury company focused on HYPE tokens, with existing Sonnet shareholders receiving Pubco common stock and contingent value rights.
Delay expected
Capital raise
Sonnet BioTherapeutics Holdings, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on September 26, 2025, to vote on director elections, executive compensation, auditor ratification, and other key governance matters.
Delay expected
Better than expected
Capital raise
DEF 14A: Sonnet BioTherapeutics Seeks Stockholder Approval for Reverse Stock Split and Equity Issuance
Sonnet BioTherapeutics is asking stockholders to approve a reverse stock split and the issuance of more than 20% of its common stock to Chardan Capital Markets to maintain its Nasdaq listing and secure funding.
Worse than expected
Capital raise
New Public Companies (S-1)
Sonnet BioTherapeutics is seeking to register up to 2,000,000 shares of common stock for potential sale by Chardan Capital Markets, aiming to raise up to $25 million through a committed equity facility.
Worse than expected
Capital raise
S-1/A: Sonnet BioTherapeutics Files for Resale of Common Stock and Warrants After Private Placements
Sonnet BioTherapeutics is registering for resale 127,500 shares of common stock and 2,303,825 shares issuable upon exercise of warrants, following recent private placements.
Capital raise
Sonnet BioTherapeutics plans to offer and sell up to 2,000,000 shares of common stock through a committed equity facility with Chardan Capital Markets, potentially raising up to $25 million.
Capital raise
Sonnet BioTherapeutics is registering for the resale of up to 127,500 shares of common stock and 2,303,825 shares issuable upon exercise of warrants by selling stockholders.
Capital raise
Sonnet BioTherapeutics plans to offer common stock and warrants to purchase common stock, aiming to raise capital for research and development, working capital, and debt repayment.
Capital raise
Sonnet BioTherapeutics is undertaking a public offering of common stock and warrants to raise capital for research and development, working capital, and general corporate purposes.
Capital raise
Schedule 13G - Passive Investments
SCHEDULE: Republic Digital's Stake in Sonnet BioTherapeutics Falls Below 5% Following Share Increase
Republic Digital Opportunistic Digital Assets Master Fund, Ltd. and Joseph Naggar's beneficial ownership in Sonnet BioTherapeutics Holdings, Inc. decreased to 4.2% after an increase in the issuer's outstanding common stock.
Capital raise